Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain

British Journal of Anaesthesia

Volumn 115, Issue 5, 2015, Pages 761-767

  Kersten, C ^a   Cameron, M G ^a   Laird, B ^b,c   Mjaland S ^a  

^a SØRLANDET HOSPITAL   (Norway)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

analgesics; epidermal growth factor; neuralgia; pain, radiating; receptor

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PANITUMUMAB; STEROID; TETRACYCLINE; ANALGESIC AGENT; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ALLERGIC REACTION; ALOPECIA; ANALGESIA; ARTICLE; ASEPTIC MENINGITIS; CANCER THERAPY; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERANCE; DYSGEUSIA; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; HYPOMAGNESEMIA; INFECTION COMPLICATION; MALE; NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN INTENSITY; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SKIN MANIFESTATION; SPIKE WAVE; STOMATITIS; WITHDRAWAL SYNDROME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; NEOPLASM; NEURALGIA; PAIN MEASUREMENT; PROCEDURES; RECURRENT DISEASE; YOUNG ADULT;

ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTIBODIES, MONOCLONAL; CETUXIMAB; ERLOTINIB HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEURALGIA; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; YOUNG ADULT;

EID: 84946140144     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aev326     Document Type: Article

References (41)

1. IASP. Part III, Pain Terms, A Current List with Definitions and Notes on Usage. In: Merskey H, Bogduk N, eds. Classification of Chronic Pain. Seattle: IASP Press, 2014
2. Laird B, Colvin L, Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer. 2008; 44: 1078-82
3. O Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. PharmacoEconomics. 2009; 27: 95-112
4. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008; 136: 380-7
5. Glover J, Dibble SL, Dodd MJ, Miaskowski C. Mood states of oncology outpatients: does pain make a difference? Journal of Pain & Symptom Management. 1995; 10: 120-8
6. Lloyd-Williams M, Dennis M, Taylor F A prospective study to determine the association between physical symptoms and depression in patients with advanced cancer. Palliat Med. 2004; 18: 558-63
7. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005; 118: 289-305
8. Colvin L, Forbes K, Fallon M. Difficult pain. Br Med J. 2006; 332: 1081-3
9. Fallon MT, Hanks GW. Opioid-resistant pain: sense or nonsense? The Pain Clinic. 1993; 6: 205-6
10. Mercadante D, Fulfaro F, Casuccio A, Barresi L. Investigation of an opioid response categorization in advanced cancer patients. Journal of Pain and SymptomManagement. 1999; 18: 347-52
11. Kersten C, Cameron MG. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Reports. 2012; doi: 10.1136/bcr.12.2011.5374: 1-6
12. Kersten C, Cameron MG, Mjaaland S. Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series. Scandinavian Journal of Pain. 2013; 4: 3-7
13. Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002; 110: 763-73
14. Limited AU. gefitinib SPC. Available from http://www. medicines.org.uk/emc/medicine/22104/SPC/.May 8th 2015 (accessed 21 August 2015).
15. Limited RP. Erlotinib SPC. Available from http://www. medicines.org.uk/emc/medicine/16781 January 24th 2015 (accessed 21 August 2015).
16. Ltd A. Panitumumab: Summary of Product Characteristics Available from http://www.medicines.org.uk/emc/medicine/.20528 April 13th 2015 (accessed 21 August 2015).
17. Serono M. Cetuximab SPC. Available from http://www. medicines.org.uk/emc/medicine/19595 August 4th 2014 (accessed 21 August 2015).
18. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008; 70: 1630-5
19. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006; 22: 1911-20
20. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23: 129-38
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, andWelfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976
22. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, PooleRM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001; 94: 149-58
23. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012; 307: 1383-93
24. Goss GD, O Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013; 31: 3320-6
25. Ocvirk J, Heeger S, McCloud P, Hofheinz RD A review of the treatment options for skin rash induced by EGFR-Targeted therapies: Evidence from randomized clinical trials and a meta-Analysis. Radiology and Oncology. 2013; 47: 166-75
26. Carroll SL, Miller ML, Frohnert PW, Kim SS, Corbett JA. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci. 1997; 17: 1642-59
27. Liu B, Neufeld AH. Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. J Neurosci Res. 2007; 85: 3523-9
28. Kanzaki H, Mizobuchi S, Obata N, et al. Expression changes of the neuregulin 1 isoforms in neuropathic pain model rats. Neurosci Lett. 2012; 508: 78-83
29. Calvo M, Zhu N, Grist J, Ma Z, Loeb JA, Bennett DL. Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway. Glia. 2011; 59: 554-68
30. Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, et al. Interferon/.STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux(R)) efficacy in KRAS wild-Type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximabadapted tumor cell-line models. Int J Oncol. 2011; 39: 1455-79
31. Ji RR. Mitogen-Activated protein kinases as potential targets for pain killers. Curr Opin Investig Drugs. 2004; 5: 71-5
32. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007; 10: 1361-8
33. Campbell TM, Main MJ, Fitzgerald EM. Functional expression of the voltage-gated Na(+)-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells. J Cell Sci. 2013; 126(Pt 21): 4939-49
34. Hilborn MD, Vaillancourt RR, Rane SG. Growth factor receptor tyrosine kinases acutely regulate neuronal sodium channels through the src signaling pathway. J Neurosci. 1998; 18: 590-600
35. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012; 53(Suppl 7): 26-33
36. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377: 2103-14
37. Tveit KM, GurenT, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012; 30: 1755-62
38. Irizarry MC, Webb DJ, Ali Z, et al. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009; 25: 469-76
39. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2005; (3): CD005452
40. Weinstein SM, Abernethy AP, Spruill SE, Pike IM, True Kelly A, Jett LG A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial. J Pain Symptom Manage. 2012; 43: 679-93
41. Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci USA. 1999; 96: 7723-30